We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Analyzer Platform for Simultaneous Detection of Multiple Sexually Transmitted Infections Is Now CE-marked

By LabMedica International staff writers
Posted on 09 Mar 2020
Print article
Image: the Vivalytic multiplex PCR platform (Photo courtesy of Randox Laboratories)
Image: the Vivalytic multiplex PCR platform (Photo courtesy of Randox Laboratories)
The British health diagnostic company Randox Laboratories (Crumlin, United Kingdom) announced receipt of CE-marking for its Biochip-based assay, which tests for 10 sexually transmitted infections (STIs) simultaneously.

The Randox patented “BAT” biochip is an innovative multiplexing technology, which is utilized within the cartridge aspect of an autoanalyzer platform. The Biochip allows for the simultaneous detection of multiple analytes from a single sample. Specifically, the Randox STI BAT assay was designed for use with the Vivalytic system, an intuitive point-of-care PCR platform, developed in partnership with the German technology company Bosch (Waiblingen, Germany).

Working in concert, from one patient sample, the assay system tests simultaneously for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), Mycoplasma genitalium (MG), Treponema pallidum (syphilis) (TP), Herpes simplex virus 1 (HSV-1), Herpes simplex virus 2 (HSV-2), Haemophilus ducreyl (HD), Mycoplasma hominis (MH), and Ureaplasma urealyticum (UU).

Dr. Peter FitzGerald, managing director of Randox Laboratories, said, “Antibiotic stewardship is a critical issue which we all have a responsibility to embrace and drive forward. The CE marking of the STI assay, which incorporates Randox Biochip Technology, will be a game-changer for clinicians and patients across Europe, by facilitating early, accurate and comprehensive diagnoses of STIs that allows for the best possible patient outcome. Never before has there been this level of accessibility and speed with regards to STI testing.”

Marc Meier, managing director of Bosch Healthcare Solutions, a subsidiary of Bosch Group, said, “We are enthusiastic about partnering with Randox to offer their assay technology on the Vivalytic platform. The core competencies of Bosch in automation, miniaturization, sensor technology and connectivity are complemented by Randox’s expertise in developing excellent biocontent for a wide range of assays and commercializing innovative diagnostic solutions.”

Related Links:
Randox Laboratories
Bosch


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more